Picture Berlin Partner Bionnale the Annual Life Sciences Event 650x80px
Document › Details

Syngulon S.A.. (5/16/20). "Press Release: Enzymicals and Syngulon Sign a Non-exclusive License Agreement on the Use of Syngulon’s Antibiotic Free Technology to Produce Enzymes". Seraing.

Organisations Organisation Syngulon S.A.
  Organisation 2 Enzymicals AG
Products Product enzyme production technology
  Product 2 industrial enzyme
Index terms Index term Enzymicals–Syngulon: enzyme production technology, 202005– license non-excl to antibiotic-free selection technology of Syngulon
  Index term 2 OTHER–Enzymicals: enzymes, 202005 service production + supply of diagnostic enzymes using antibiotic-free production for undisclosed world leader
Persons Person Menyes, Ulf (Enzymicals 202203– Advisor before CEO)
  Person 2 Hélin, Guy (Syngulon 201809 CEO + Co-Founder)

Enzymicals AG, a German enterprise focusing on industrial biocatalysis and Syngulon, a Belgian synthetic biology company developing original genetic technologies using bacteriocins, announce a non-exclusive license agreement which provides Enzymicals access to Syngulon’s patented selection technology.

Syngulon’s technology expands the capacity for selection of microorganisms. Synthetic biology uses the concept of “bioengineering” to improve or modify existing genetic systems to create microbes with desired behaviors, and Syngulon uses this approach to develop its selection technology (US patent 9,333,227/10,188,114). It is based on bacteriocins, ribosomally-produced peptides naturally made by most bacteria to kill competitive microbial species. This technology offers advantageous over antibiotic selection for several reasons: it avoids the use of antibiotics in the first place, helping to reduce the spread of antibiotic resistant microbes. The technology also increases product yield; as bacteriocins are generally smaller peptides, they do not impose a heavy metabolic burden on the producing cell. They can have a wide target specificity, helping to avoid genetic drift. Finally, the system is 100% plasmid-based (e.g. without chromosomal mutations), making it applicable for use in any E. coli strains.

Enzymicals offers a broad selection of recombinant enzymes suitable for research, development, production and diagnostics as well as a tailor-made protein expression and optimization service. There is a growing interest for antibiotic-free production of enzymes coming from customers and the technology is currently applied in a first project for the production of diagnostic enzymes for a world leader that requires antibiotic-free production.

Dr. Ulf Menyes, CEO of Enzymicals AG, states “This genetic technology will make our microbial strains involved in industrial processes safer and more efficient. We are happy to now use this innovation in our own applications as well as for specific developments for our clients.”

Guy Hélin, CEO of Syngulon, added “This is the second license agreement that we announce on our technologies and we are very happy to work with Enzymicals on their project for a world leader in diagnostic enzymes”

Contact Author

+32 475470708
Email >

Record changed: 2022-02-05


Picture [iito] No Tracking 650x100px

More documents for Syngulon S.A.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Bionnale the Annual Life Sciences Event 650x80px

» top